Minimally Invasive Medicine (00853) is now down more than 6%. As of press release, it is down 6.22% to HK$6.8 million, with a turnover of HK$177 million.
The Zhitong Finance App learned that Minimally Invasive Healthcare (00853) has now declined by more than 6%. As of press release, it is down 6.22% to HK$6.8 million, with a turnover of HK$177 million.
CITIC Construction Investment pointed out that in 2023, due to multiple adverse factors such as insufficient production capacity for some of the company's products, domestic procurement, and increased domestic industry compliance requirements, the company's revenue side performance growth in 2023 was slightly lower than market expectations. Looking ahead to 2024, the company's coronary, orthopedic and heart rhythm management businesses are expected to maintain steady growth; surgical robotics, neurological intervention, heart valve and aortic and peripheral intervention businesses are expected to drive the company's overall performance to achieve rapid growth. As the company's various cost reduction and efficiency measures continue to advance, the company's profit-side losses are expected to narrow drastically in the future and eventually achieve profit.
Furthermore, the company recently announced a convertible bond financing agreement, and the company's liquidity problems have basically been resolved. According to the convertible bond financing agreement announcement, minimally invasive medical treatment will shift from research and development oriented to performance oriented in the future. Nomura said that the situation may improve in the short term, and the long-term debt problem is still difficult.